Watch for FDA acceptance of the NDA and PDUFA date assignment, which typically triggers a binary catalyst within 6-10 months. ESMO 2026 data presentation in October may provide further detail on SAFFRON efficacy magnitude.
Price Chart
Executive Summary
AstraZeneca submitted an NDA to the FDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET-overexpressed/amplified NSCLC after EGFR-TKI progression, supported by the positive SAFFRON Phase III trial showing statistically significant PFS and OS improvements. This is a major regulatory milestone for HUTCHMED's partnered asset, potentially expanding its US label beyond China approvals.
Key Facts
- NDA submitted to FDA for ORPATHYS (savolitinib) + TAGRISSO (osimertinib) in MET-overexpressed/amplified locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy
- SAFFRON global Phase III trial (n=338) met primary endpoint of PFS and key secondary endpoint of OS with statistical significance vs platinum-based chemotherapy
- SAFFRON results to be presented at ESMO 2026 Presidential Symposium
- ORPATHYS already approved in China for MET exon 14 skipping NSCLC, MET-amplified gastric cancer, and in combination with TAGRISSO for EGFRm NSCLC with MET amplification
- Combination granted temporary authorization in Switzerland based on SAVANNAH Phase II trial
- HUTCHMED and AstraZeneca jointly developed ORPATHYS; AstraZeneca commercializes it
Financial Impact
US approval would open a large addressable market: ~34% of EGFR-TKI-resistant NSCLC tumors develop high MET overexpression/amplification, representing a significant unmet need. No revenue figures stated.
Risk Factors
- FDA may issue a Complete Response Letter (CRL) on safety/efficacy or CMC grounds, delaying or denying approval
- Competing MET-targeted therapies (e.g., tepotinib, capmatinib) could limit commercial uptake
- Regulatory review timeline is uncertain and could extend beyond standard PDUFA
- Reliance on AstraZeneca for commercialization reduces HUTCHMED's direct control over US launch
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370345 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+20 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+20 | — | — |
Oct 21, 2026 5d ago | 6-K | $14.37 | awaiting T+20 | — | $14.27 (−0.70%) |
Sep 29, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 28, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 29, 2026 27d ago | Press Release | $14.63 | awaiting T+20 | — | $14.27 (−2.46%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $14.27 (+2.66%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $14.27 (+2.37%) |
Sep 3, 2026 7w ago | 6-K | $14.11 $14.20 | ▲ +0.64% | ▲ +1.83% | $14.27 (+1.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers